Antitumor drugs with known, probable, or presumed cardiotoxicity
| Anthracyclines and Nonanthracycline Antibiotics | Nonanthracycline Chemotherapeutics | Targeted Drugs | |
|---|---|---|---|
| Antibodies | TKIs | ||
| Anthracyclines (doxorubicin, epirubicin, daunorubicin, idarubicin) | Alkylating agents (cyclophosphamide, ifosfamide, cisplatin, busulfan) | Anti-HER-2 (trastuzumab) | Anti-HER-2/HER-1 (lapatinib) |
| Nonanthracycline antibiotics (mitoxantrone, bleomycin, mitomycin) | Tubulin-active agents: vinca alkaloids (vincristine, vinblastine); taxanes (paclitaxel, docetaxel)* | Anti-VEGF (bevacizumab) | Anti-VEGFr (sunitinib, sorafenib) |
| Antimetabolites (fluoropyrimidines, methothrexate, fludarabine, cytarabine) | Anti-Bcr/Abl, anti-C-Kit (imatinib, dasatinib, nilotinib) | ||
| Topoisomerase II inhibitors (etoposide) | |||
↵* Cardiotoxicity is caused also by hypersensitivity reactions to vehicle, particularly in the case of paclitaxel; taxanes may aggravate anthracycline-related cardiotoxicity.
Based on Albini et al. (2010), Carver et al. (2007), Cheng and Force (2010), and Menna et al. (2008).